Business Description
Neurocrine Biosciences Inc
NAICS : 325414
SIC : 2836
ISIN : US64125C1099
Share Class Description:
NBIX: Ordinary SharesCompare
Compare
Traded in other countries / regions
NBIX.USAN1BI34.Brazil0K6R.UKNB3.Germany IPO Date
1996-05-23Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.89 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.44 | |||||
| Interest Coverage | 4.18 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 10.75 | |||||
| Beneish M-Score | -2.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.4 | |||||
| 3-Year EBITDA Growth Rate | 32.8 | |||||
| 3-Year EPS without NRI Growth Rate | -11.5 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | 23.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.35 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.59 | |||||
| 9-Day RSI | 57.54 | |||||
| 14-Day RSI | 54.54 | |||||
| 6-1 Month Momentum % | -18.98 | |||||
| 12-1 Month Momentum % | 1.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.37 | |||||
| Quick Ratio | 4.26 | |||||
| Cash Ratio | 2.86 | |||||
| Days Inventory | 423.49 | |||||
| Days Sales Outstanding | 73.47 | |||||
| Days Payable | 1083.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.8 | |||||
| Shareholder Yield % | -0.77 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.52 | |||||
| Operating Margin % | 26.23 | |||||
| Net Margin % | 17.21 | |||||
| FCF Margin % | 19.62 | |||||
| ROE % | 16.29 | |||||
| ROA % | 11.76 | |||||
| ROIC % | 21.48 | |||||
| 3-Year ROIIC % | -77 | |||||
| ROC (Joel Greenblatt) % | 122.1 | |||||
| ROCE % | 20.32 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.58 | |||||
| Forward PE Ratio | 19.07 | |||||
| PE Ratio without NRI | 28.58 | |||||
| Shiller PE Ratio | 168.79 | |||||
| Price-to-Owner-Earnings | 81.21 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 5.63 | |||||
| PB Ratio | 4.52 | |||||
| Price-to-Tangible-Book | 4.58 | |||||
| Price-to-Free-Cash-Flow | 28.59 | |||||
| Price-to-Operating-Cash-Flow | 26.38 | |||||
| EV-to-EBIT | 20.42 | |||||
| EV-to-Forward-EBIT | 10.2 | |||||
| EV-to-EBITDA | 19.51 | |||||
| EV-to-Forward-EBITDA | 10.66 | |||||
| EV-to-Revenue | 5 | |||||
| EV-to-Forward-Revenue | 4.17 | |||||
| EV-to-FCF | 25.51 | |||||
| Price-to-Projected-FCF | 2.05 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.14 | |||||
| Price-to-Graham-Number | 2.41 | |||||
| Price-to-Net-Current-Asset-Value | 11.6 | |||||
| Price-to-Net-Cash | 29.86 | |||||
| Earnings Yield (Greenblatt) % | 4.9 | |||||
| FCF Yield % | 3.58 | |||||
| Forward Rate of Return (Yacktman) % | 22.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NBIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurocrine Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,242.8 | ||
| EPS (TTM) ($) | 3.73 | ||
| Beta | 0.17 | ||
| Volatility % | 23.94 | ||
| 14-Day RSI | 54.54 | ||
| 14-Day ATR ($) | 3.359487 | ||
| 20-Day SMA ($) | 116.977 | ||
| 12-1 Month Momentum % | 1.39 | ||
| 52-Week Range ($) | 103.63 - 157.9799 | ||
| Shares Outstanding (Mil) | 101.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurocrine Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurocrine Biosciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neurocrine Biosciences Inc Frequently Asked Questions
What is Neurocrine Biosciences Inc(NBIX)'s stock price today?
The current price of NBIX is $121.53. The 52 week high of NBIX is $157.98 and 52 week low is $103.63.
When is next earnings date of Neurocrine Biosciences Inc(NBIX)?
The next earnings date of Neurocrine Biosciences Inc(NBIX) is 2025-02-07 Est..
Does Neurocrine Biosciences Inc(NBIX) pay dividends? If so, how much?
Neurocrine Biosciences Inc(NBIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers